Novartis dropped out of the company’s deal to fund Mesoblast’s floundering COVID-19 treatment.
Coronavirus vaccines are known to be less protective in people with the blood cancer multiple myeloma, such as former U.S. Secretary of State Colin Powell, who died on Oct. 18 of complications from Covid-19 despite being fully vaccinated. Additionally, in a paper in the journal Stem Cell Reports, researchers said numerous businesses have made unsubstantiated and inaccurate claims about supposed stem cell products to treat Covid-19.
BrainStorm Cell Therapeutics, one of the leading developers of adult stem cell therapies that mainly focuses on adult neurodegenerative diseases, reported that the company’s 28-week-long Phase II clinical trial for progressive multiple sclerosis (MS) came to a close.
Melbourne, Australia and New York-based Mesoblast Limited announced that in a study of COVID-19 patients with moderate to severe acute respiratory distress syndrome, there was 83 percent survival with two intravenous infusions of the company’s experimental allogeneic mesenchymal stem cell candidate Ryoncil (remestemcel-L).
German drugmaker Bayer is paying up to $600 million for full control of cell therapy developer BlueRock Therapeutics.
Orchard Therapeutics secured an exclusive license for an ex vivo autologous hematopoietic stem cell gene therapy program for the treatment of MPS-I developed by SR-Tiget.
Orchard Therapeutics announced positive results from a two-year follow up of a stem cell gene therapy for severe combined immune deficiency due to adenosine deaminase deficiency (ADA-SCID).
Shares of Belgium-based TiGenix NV shot up after Japan’s Takeda Pharmaceutical opted to acquire the company for $630 million.
The FDA will fast track the review of Australian drug developer Mesoblast Ltd.’s cell therapy treatment for heart failure patients under a new designation rolled out in December 2016.
Canada’s Aeterna Zentaris Inc. said the U.S. FDA approved its oral test to diagnose adult growth hormone deficiency.